Malignant pilomatricoma: a case report

Waxtein, Leon; Vega, Elisa; Alvarez, L; Cortés‐Franco, Roberto; T, Hojyo; Domínguez‐Soto, Luciano

doi:10.1046/j.1365-4362.1998.00503.x

Cited by 13 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A mean size of 4 cm, as was identified in our case, among 60 patients with pilomatrix carcinoma has been reported (12). The majority of the lesions are located in the head-and-neck region, particularly in the preauricular area, scalp, posterior neck and upper back (12,15,16). A very small number of cases have been reported to arise from the parotid region, as in our patient (17).…”

Section: Discussionsupporting

confidence: 66%

Pilomatrix carcinoma: More malignant biological behavior than was considered in the past

Papadakis

Bree

Floros

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Pilomatrix carcinoma is a very rare malignancy, with ~130 cases reported in the literature. In the past, pilomatrix carcinoma was considered to be a low-grade malignant tumor. Currently, however, its significant recurrence and metastatic potential has been well documented. Lymph node and systemic metastases are frequently observed. Wide surgical excision of the primary lesion is the principal modality of treatment, whereas adjuvant radiotherapy may be beneficial in local tumor control. Lymph node metastases may be treated surgically or with radiotherapy. Systemic disease is not responsive to chemotherapy, and is hence associated with a poor prognosis. Since the majority of nodal and systemic metastases present after the initial diagnosis and treatment, follow-up examinations of these patients may be warranted, despite the currently inadequate treatment options. In the present study, a case of pilomatrix carcinoma of the parotid region with early local recurrence only 2 months after complete excision with negative surgical margins is reported. The local recurrence was treated by excision and radiotherapy. The associated literature is also discussed.

show abstract

Section: Discussionsupporting

confidence: 66%

Pilomatrix carcinoma: More malignant biological behavior than was considered in the past

Papadakis

Bree

Floros

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Malignant pilomatrixomas are not common with 76 well‐documented cases described in the English language literature, most occurring as single‐case reports 10,23–69 . Lopansri and Mihm first described this entity in 1980 citing five previously published tumours with similar characteristics 35,39,42,54,56,57 .…”

mentioning

confidence: 99%

Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding β‐catenin

et al. 2004

View full text Add to dashboard Cite

Mutations in beta-catenin are present in benign pilomatrixomas. beta-catenin is a downstream effector in the WNT-signalling pathway, acting as a signal for differentiation and proliferation. Mutations in CTNNB1, the gene encoding beta-catenin, are present in a wide variety of benign and malignant neoplasms. We examined beta-catenin in a series of pilomatrix carcinomas (15 cases) by using immunohistochemistry and DNA sequencing of exon 3 from CTNNB1, and compared these to a series of benign pilomatrixomas (13 cases). All 11 pilomatrix carcinomas available for examination showed nuclear localization of beta-catenin and mutations in exon 3 similar to those demonstrated in benign pilomatrixomas. Two of 11 pilomatrix carcinomas showed significant nuclear accumulation of p53, whereas this was absent in all 13 benign pilomatrixomas. Expression of nuclear cyclin D1 was similar in both benign pilomatrixomas and pilomatrix carcinomas. Clinical follow-up from the 15 malignant cases reported in this study and by others indicates that wide excision offers superior control of local recurrence, compared to simple excision. Immunohistochemical and molecular analysis of beta-catenin reveals that both pilomatrix carcinomas and benign pilomatrixomas harbour mutations in beta-catenin. This implies a common initial pathogenesis and is compatible with the proposition that pilomatrix carcinomas may at least on occasion arise from their benign counterparts.

show abstract

“…Las variedades descritas de este tumor son: exofítica, bulosa, linfangiectásica, anetodérmica y perforante 10,11 . También pueden tener una degeneración maligna aunque muy rara 12 .…”

Section: Discussionunclassified

Pilomatrixoma nasal: Nasal pilomatricoma

et al. 2009

Rev. Otorrinolaringol. Cir. Cabeza Cuello

View full text Add to dashboard Cite

show abstract

Malignant pilomatricoma: a case report

Cited by 13 publications

References 12 publications

Pilomatrix carcinoma: More malignant biological behavior than was considered in the past

Pilomatrix carcinoma: More malignant biological behavior than was considered in the past

Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding β‐catenin

Pilomatrixoma nasal: Nasal pilomatricoma

Contact Info

Product

Resources

About